Methylprednisolone: Likely an Effective Treatment in Acute Respiratory Distress Syndrome

Corticosteroid Guideline Task Force of SCCM and ESICM

doi:10.1097/CCM.0000000000003572

Methylprednisolone: Likely an Effective Treatment in Acute Respiratory Distress Syndrome

Corticosteroid Guideline Task Force of SCCM and ESICM

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E374-E375
Journal	Critical care medicine
Volume	47
Issue number	4
DOIs	https://doi.org/10.1097/CCM.0000000000003572
State	Published - Apr 2019

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine

Access to Document

10.1097/CCM.0000000000003572

Cite this

@article{458f0733fbc94f9d98d045e376a5cc87,

title = "Methylprednisolone: Likely an Effective Treatment in Acute Respiratory Distress Syndrome",

author = "{Corticosteroid Guideline Task Force of SCCM and ESICM} and {Umberto Meduri}, G. and Bram Rochwerg and Djillali Annane and Pastores, {Stephen M.} and Wiebke Arlt and Josef Briegel and Albertus Beishuizen and Balk, {Robert A.} and Joseph Carcillo and Mirjam Christ-Crain and Cooper, {Mark S.} and Marik, {Paul E.} and Olsen, {Keith M.} and Rodgers, {Sophia C.} and Russell, {James A.} and {Van den Berghe}, Greet",

note = "Funding Information: All authors disclosed off-label product use of glucocorticoids, as there are no Food and Drug Administration-approved therapies for acute respiratory distress syndrome. Dr. Matthay{\textquoteright}s institution has received funding from Bayer, GlaxoSmithKline, and Amgen. He has received other support from Roche/Genentech (Chair, Data Safety Monitoring Board), Cerus Therapeutics (consultant), CSL Behring (consultant), Boehringer Ingelheim (consultant), and Quark Pharmaceuticals (consultant). Dr. Calfee's institution has received research funding from the National Institutes of Health, GlaxoSmithKline, and Bayer. Dr. Calfee has served on advisory boards or as a consultant for GlaxoSmithKline, Bayer, CSL Behring, Boehringer Ingelheim, Prometic, and Roche/Genentech. Funding Information: Dr. Meduri received support for article research from the Veteran Administration; he disclosed government work; he disclosed off-label product use of methylprednisolone in acute respiratory distress syndrome; and he disclosed that this material is the result of work supported with the resources and use of facilities at the Memphis Veteran Administration Medical Center. The contents of this commentary do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. Dr. Pastores received funding from McGraw-Hill (royalties), La Jolla Pharmaceuticals (advisory board), and the Society of Critical Care Medicine (Board Review Course lectures). The remaining authors have disclosed that they do not have any potential conflicts of interest.",

year = "2019",

month = apr,

doi = "10.1097/CCM.0000000000003572",

language = "English (US)",

volume = "47",

pages = "E374--E375",

journal = "Critical care medicine",

issn = "0090-3493",

publisher = "Lippincott Williams and Wilkins",

number = "4",

}

TY - JOUR

T1 - Methylprednisolone

T2 - Likely an Effective Treatment in Acute Respiratory Distress Syndrome

AU - Corticosteroid Guideline Task Force of SCCM and ESICM

AU - Umberto Meduri, G.

AU - Rochwerg, Bram

AU - Annane, Djillali

AU - Pastores, Stephen M.

AU - Arlt, Wiebke

AU - Briegel, Josef

AU - Beishuizen, Albertus

AU - Balk, Robert A.

AU - Carcillo, Joseph

AU - Christ-Crain, Mirjam

AU - Cooper, Mark S.

AU - Marik, Paul E.

AU - Olsen, Keith M.

AU - Rodgers, Sophia C.

AU - Russell, James A.

AU - Van den Berghe, Greet

N1 - Funding Information: All authors disclosed off-label product use of glucocorticoids, as there are no Food and Drug Administration-approved therapies for acute respiratory distress syndrome. Dr. Matthay’s institution has received funding from Bayer, GlaxoSmithKline, and Amgen. He has received other support from Roche/Genentech (Chair, Data Safety Monitoring Board), Cerus Therapeutics (consultant), CSL Behring (consultant), Boehringer Ingelheim (consultant), and Quark Pharmaceuticals (consultant). Dr. Calfee's institution has received research funding from the National Institutes of Health, GlaxoSmithKline, and Bayer. Dr. Calfee has served on advisory boards or as a consultant for GlaxoSmithKline, Bayer, CSL Behring, Boehringer Ingelheim, Prometic, and Roche/Genentech. Funding Information: Dr. Meduri received support for article research from the Veteran Administration; he disclosed government work; he disclosed off-label product use of methylprednisolone in acute respiratory distress syndrome; and he disclosed that this material is the result of work supported with the resources and use of facilities at the Memphis Veteran Administration Medical Center. The contents of this commentary do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. Dr. Pastores received funding from McGraw-Hill (royalties), La Jolla Pharmaceuticals (advisory board), and the Society of Critical Care Medicine (Board Review Course lectures). The remaining authors have disclosed that they do not have any potential conflicts of interest.

PY - 2019/4

Y1 - 2019/4

UR - http://www.scopus.com/inward/record.url?scp=85063261081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063261081&partnerID=8YFLogxK

U2 - 10.1097/CCM.0000000000003572

DO - 10.1097/CCM.0000000000003572

M3 - Letter

C2 - 30882439

AN - SCOPUS:85063261081

SN - 0090-3493

VL - 47

SP - E374-E375

JO - Critical care medicine

JF - Critical care medicine

IS - 4

ER -

Methylprednisolone: Likely an Effective Treatment in Acute Respiratory Distress Syndrome

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this